Miacalcic (Calcitonin)

Calcitonin binds to specific receptors on osteoclast cells, the cells responsible for breaking down bone. This binding triggers a signaling pathway that suppresses osteoclast activity and promotes their apoptosis, thereby decreasing bone resorption. The reduced release of calcium from bone lowers serum calcium levels and helps stabilize bone structure.

The dosage of Miacalcic is individualized by the prescribing healthcare professional based on the patient’s condition, severity, and response to therapy. The prescriber determines the amount, frequency, and route of administration, and any adjustments are made according to clinical monitoring and laboratory results.

Safety data for calcitonin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Miacalcic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

The primary alternative class for bone‑related calcium disorders is bisphosphonates. While bisphosphonates inhibit osteoclasts by binding to bone mineral, calcitonin acts directly on calcitonin receptors to rapidly reduce bone resorption and serum calcium. Calcitonin often has a faster onset but a shorter duration of effect, whereas bisphosphonates provide longer‑term bone protection.

Miacalcic must be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If the temperature rises above the recommended range, discard the product as potency may be compromised.

Miacalcic is supplied as an injectable solution and can be given by intramuscular, intravenous, or subcutaneous injection, depending on the clinical indication and prescriber’s preference. Administration is performed by a qualified healthcare professional using aseptic technique, and the injection site should be monitored for local reactions.

The most serious adverse events include severe hypocalcemia, which can cause muscle cramps, tetany or cardiac arrhythmias, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of low calcium and any sudden allergic symptoms, and treatment should be stopped immediately if these occur.

Miacalcic is contraindicated in individuals with known hypersensitivity to calcitonin or any of its excipients. It should also be avoided in patients with a history of medullary thyroid carcinoma or in those where calcium levels are already low, unless a specialist determines that the benefits outweigh the risks.